Publisher
Springer Science and Business Media LLC
Reference96 articles.
1. International Agency for Research on Cancer. OC statistics. Geneva: Globocan, World Health Organization; 2020. https://gco.iarc.fr/today/data/factsheets/cancers/25-Ovary-fact-sheet.pdf (viewed June 2024)
2. Sideris M, Menon U, Manchanda R (2024) Screening and prevention of ovarian cancer. Med J Australia 220:264–274
3. Zhang L, Chen Y, Wang K (2019) Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer 43:135–144
4. Barani M, Bilal M, Sabir F, Rahdar A, Kyzas GZ (2021) Nanotechnology in ovarian cancer: diagnosis and treatment. Life Sci 266:118914
5. Ray-Coquard I, Leary A, Pignata S, Cropet C, González-Martín A, Marth C, Nagao S, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alia EM, Bogner G, Yoshida H, Lefeuvre-Plesse C, Buderath P, Mosconi AM, Lortholary A, Burges A, Medioni J, El-Balat A, Rodrigues M, Park-Simon TW, Dubot C, Denschlag D, You B, Pujade-Lauraine E, Harter P (2023) PAOLA-1/ENGOT-ov25 investigators. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann Oncol 34:681–692